
Cefiderocol Demonstrates Better Outcomes as Empiric or Documented Therapy as Compared to Salvage Therapy
New data being presented at the upcoming ESCMID Global 2025 will show cefiderocol (Fetroja) had a higher clinical cure rate trend among patients who received cefiderocol for a documented infection (67.4%) or as empiric therapy (64.6%) as compared to those …